
Feb 28 (Reuters) - EMA's CHMP:
EMA'S CHMP: VYJUVEK (BEREMAGENE GEPERPAVEC) RECEIVE POSITIVE OPINION TO TREAT WOUNDS IN PATIENTS OF ALL AGES WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA
EMA SAYS CHMP: CONCLUDED THAT ITS OPINION RECOMMENDING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) DOES NOT NEED TO BE UPDATED
EMA'S CHMP: EXTENSION TO EXISTING INDICATION OF CHIKUNGUNYA VACCINE IXCHIQ TO INCLUDE ACTIVE IMMUNISATION OF ADOLESCENTS FROM 12 YEARS OF AGE
EMA'S CHMP: FABHALTA GETS POSITIVE OPINION FOR EXTENSION OF INDICATION FOR TREATMENT OF ADULT PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY
EMA'S CHMP: RECOMMENDS APPROVAL OF DEQSIGA FOR PRIMARY, SECONDARY IMMUNODEFICIENCIES AND AUTOIMMUNE DISEASE IMMUNOMODULATION
Source text: [ID:]
Further company coverage: KRYS.O